PHARMACEUTICAL 2023

ELI Lilly Co
Rank 291 of 471



PHARMACEUTICAL 2023

ELI Lilly Co
Rank 291 of 471

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 63% points.The greatest weakness of ELI Lilly Co is the variable Stockholders Equity, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 204%, being 41% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	18,034,500
Cost of Goods Sold	6,629,800
Intangible Assets	11,279,600
Liabilities, Current	17,138,200
Liabilities, Non-Current	21,576,200
Other Assets	10,031,700
Other Compr. Net Income	498,500
Other Expenses	2,035,600
Other Liabilities	0
Other Net Income	0
Other Revenues	28,541,400
Property and Equipment	10,144,000
Research and Development	7,190,800
Selling, General and Administrative Expense	6,440,400

Output Variable	Value in 1000 USD
Assets	49,489,800
Liabilities	38,714,400
Expenses	22,296,600
Revenues	28,541,400
Stockholders Equity	10,775,400
Net Income	6,244,800
Comprehensive Net Income	6,494,050
BaseVar	69,770,350
ECR before LimitedLiability	68%
Economic Capital Ratio	204%